Compare Immunovant Inc. Common Stock (IMVT) vs iShares Global Tech ETF (IXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs iShares Global Tech ETF — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while iShares Global Tech ETF trades at $148.87 (market cap $10.08B). The key difference: iShares Global Tech ETF is the larger of the two by market cap, and iShares Global Tech ETF is trading nearer its 52-week high, Immunovant Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and iShares Global Tech ETF for 46 Days on average.
| IMVT | IXN | |
|---|---|---|
Market Cap | $6.62B | $10.08B |
Volume | 1,131,364 | 134,463 |
Sector | Health | Sector/Thematic |
52-Week High | $44.96 | $152.94 |
52-Week Low | $17.03 | $95.76 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $5.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IXN trades at $152.16, down 0.51% today but near its 52-week high of $151.40, reflecting strong momentum. Technical indicators show a bullish moving average signal but overbought RSI levels. Recent news highlights the ETF's 34% gain and multiple compression, with a high-teens P/E ratio and 28.5% long-term EPS growth rate, emphasizing global tech exposure beyond the U.S.
The outlook remains positive due to AI exposure and global diversification, but risks include portfolio concentration and overbought conditions. Analyst sentiment is bullish, with buy ratings citing valuation appeal, though investors should monitor tech sector volatility and competitive pressures from international firms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About iShares Global Tech ETF
IXN provides exposure to global electronics, software, and hardware companies. It tracks the S&P Global 1200 Information Technology Index, covering tech leaders across both developed and emerging markets.
Read more on IXN →
